Pre-Emptive Analgesia Efficacy of Etoricoxib for Postoperative Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00149253
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : September 8, 2005
Information provided by:
Khon Kaen University

September 6, 2005
September 8, 2005
September 8, 2005
December 2004
Not Provided
  • The primary end points were morphine consumption within 24-hr post-operatively
  • and total pain relief over 8 h (TOPAR8).
Same as current
No Changes Posted
Patient global response to therapy
Same as current
Not Provided
Not Provided
Pre-Emptive Analgesia Efficacy of Etoricoxib for Postoperative Pain
A Randomized, Double-Blind, Controlled Trial of Etoricoxib as a Pre-Emptive Analgesic for Abdominal Hysterectomy
Taken together, studies of the value of pre-emptive analgesia are inconclusive. This randomized, double-blind, dose-ranging, placebo-controlled study was therefore designed to test that a reduction in post-operative morphine consumption can be achieved by a single-dose of etoricoxib before induction of anesthesia.
Patients undergoing transabdominal hysterectomy were randomized to a group taking a single dose (orally) of etoricoxib 120 mg (n = 18), etoricoxib 180 mg (n = 17) or placebo (n = 15) 2 hours before surgery under the same standardized general anesthesia. At the post-anesthetic care unit, intravenous morphine titration was given before starting self-controlled analgesia (PCA) device. Morphine consumption, pain relief score, sedative score, global evaluation score, and side-effects were recorded at 1, 2, 4, 8 and 24 h post-operatively. The primary end points were morphine consumption within 24-hr post-operatively and total pain relief over 8 h (TOPAR8). Patient global satisfaction was also assessed.
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • a Single-Dose of Etoricoxib
  • Post-Operative Morphine Consumption
  • Total Pain Relief Over 8 Hr(TOPAR8)
  • Post Transabdominal Hysterectomy
Drug: a single-dose of Etoricoxib before induction of anesthesia
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2005
Not Provided

Inclusion Criteria:

  • The ASA I or II patients undergoing elective transabdominal hysterectomy with general anesthesia

Exclusion Criteria:

  • Patients with history of opioid addiction or chronic pain
  • Allergy to other nonsteroidal anti-inflammatory, or asthma
  • Concomitant use of tricyclic antidepressants, opioid analgesics, antihistamines, tranquilizers, hypnotics, sedatives, or systemic corticosteroids
  • Those unable to understand the principle of patient-controlled analgesia(PCA) device were excluded from the study
Sexes Eligible for Study: Female
15 Years to 65 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
acute pain service
Faculty of Medicine,KhonKaenU
Not Provided
Not Provided
Not Provided
Not Provided
Khon Kaen University
Not Provided
Principal Investigator: waraporn chau-in, Asso Prof. Department of Anesthesiology, Faculty of Medicine,KhonKaen University,KhonKaen 40002, Thailand
Khon Kaen University
October 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP